FORBES-TATE
Lobbying for NOVARTIS, INC. · Multinational biopharmaceutical company
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.